Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity

You are here

Research Type: 
Research Duration: 
January 2017 to December 2017
Sponsors, Funders Partners: 

Gilead Protocol GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS9883 /Emtricitabine Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children